Acro Biomedical Co., Ltd.
ACBM· OTC
ACBMAcro Biomedical Co., Ltd.
Filed Apr 15, 2022 · 10-K · 105 days after period end · 0001640334-22-000809
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $598.00K | $0.00 | $193.54K | $1.35M |
| Net Income | -$3.85M | -$61.77K | -$75.87K | -$75.02K |
| EPS Diluted | — | — | $0.00 | $0.00 |
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Apr 15, 2022 · 105 d after period end
